EMA’s update on Brexit preparedness

The European Medicines Agency (EMA) has confirmed that its Brexit preparedness continuity plan has entered into its third phase on 1st October 2018. In this stage, “EMA will now temporarily suspend or scale back additional activities to ensure that resources can be redeployed so that its core activities can continue without interruption and to the same quality”, said Noël Wathion, EMA’s Deputy Executive Director.

The EMA’s prime focus for now is to ensure continuity of evaluating and supervising the medicines, while preparing for the Brexit and possible consequential staff loss.

Further reductions and suspensions are expected as part of phase 4, launched just after 1st January 2018 ahead of the EMA’s relocation to Amsterdam.

We previously informed about the EMA’s progress in its Brexit preparedness plan. The full Plan is available here.


Tagged with

Published on 12. October 2018 in News, News EU, News UK